Eli Lilly’s $3.2 Billion Bet on Gut Health

Eli Lilly announces plans to acquire Morphic Holding for $3.2 billion, aiming to expand its immunology pipeline with oral integrin therapies for inflammatory bowel disease.

Key points:

  • The acquisition centers on MORF-057, an oral α4β7 integrin inhibitor currently in Phase 2 trials for ulcerative colitis and Crohn’s disease.
  • Lilly will pay $57 per share in cash, representing a 79% premium to Morphic’s closing stock price on July 5, 2024.
  • The deal is expected to close in the third quarter of 2024, subject to customary closing conditions.

Market estimate: The global inflammatory bowel disease treatment market to reach $30.4 billion by 2031, growing at a CAGR of 3.5% from 2023 to 2031, according to Allied Market Research.


Pharmaceutical Giant Makes Strategic Move

In a bold move to expand its inflammatory bowel disease (IBD) portfolio, Eli Lilly (NYSE: LLY) announced plans to acquire Morphic Holding (NASDAQ: MORPH) for a staggering $3.2 billion. Morphic’s shares ended Monday higher by 75% in response to the news.

This acquisition aims to bolster Lilly’s immunology pipeline with innovative oral integrin therapies, potentially transforming the landscape of IBD treatment.

Eli Lilly and Company logo.

Groundbreaking Oral Therapy at the Center

The crown jewel of this acquisition is MORF-057, Morphic’s lead program. This oral α4β7 integrin inhibitor is currently undergoing Phase 2 trials for both ulcerative colitis and Crohn’s disease.

Dr. Daniel Skovronsky, Lilly’s chief scientific officer, emphasized the potential of oral therapies to “open up new possibilities for earlier intervention” and provide combination therapy options for severe cases.

Financial Details and Market Impact

Lilly’s offer of $57 per share in cash represents a significant 79% premium over Morphic’s closing stock price on July 5, 2024.

This generous valuation underscores Lilly’s confidence in Morphic’s technology and its potential to disrupt the IBD treatment market, currently valued at $22.4 billion and projected to reach $30.4 billion by 2031.

Expanding Beyond IBD

While MORF-057 is the headline attraction, Morphic’s pipeline includes preclinical molecules targeting autoimmune diseases, pulmonary hypertension, fibrosis, and cancer.

This diverse portfolio aligns with Lilly’s broader strategy to dominate the immunology field.

Source: https://www.prnewswire.com/news-releases/lilly-to-acquire-morphic-to-improve-outcomes-for-patients-with-inflammatory-bowel-disease-302190489.html

Image Source: Morphic


Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

BioMediaHub Logo